166 related articles for article (PubMed ID: 7285873)
1. Tamoxifen aziridines: effective inactivators of the estrogen receptor.
Robertson DW; Wei LL; Hayes JR; Carlson KE; Katzenellenbogen JA; Katzenellenbogen BS
Endocrinology; 1981 Oct; 109(4):1298-300. PubMed ID: 7285873
[TBL] [Abstract][Full Text] [Related]
2. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
Miller MA; Lippman ME; Katzenellenbogen BS
Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
[TBL] [Abstract][Full Text] [Related]
3. Extensive in situ activation of nuclear estrogen receptors after exposure of murine uteri to [3H]estradiol or [3H]4-hydroxytamoxifen.
Pavlik EJ; Nelson K; van Nagell JR; Donaldson ES; Walden ML; Gallion H; Kenady DE
Endocrinology; 1987 Apr; 120(4):1608-14. PubMed ID: 3830064
[TBL] [Abstract][Full Text] [Related]
4. Biological activity and receptor binding of a strongly interacting estrogen in human breast cancer cells.
Reiner GC; Katzenellenbogen BS; Bindal RD; Katzenellenbogen JA
Cancer Res; 1984 Jun; 44(6):2302-8. PubMed ID: 6547074
[TBL] [Abstract][Full Text] [Related]
5. Modulation of rat uterine steroid hormone receptors by estrogen and antiestrogen.
Dix CJ; Jordan VC
Endocrinology; 1980 Dec; 107(6):2011-20. PubMed ID: 7191796
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the estrogen receptor and its dynamics in MCF-7 human breast cancer cells using a covalently attaching antiestrogen.
Monsma FJ; Katzenellenbogen BS; Miller MA; Ziegler YS; Katzenellenbogen JA
Endocrinology; 1984 Jul; 115(1):143-53. PubMed ID: 6734512
[TBL] [Abstract][Full Text] [Related]
7. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of estrogen receptors covalently labeled with an estrogen and an antiestrogen in several estrogen target cells as studied by limited proteolysis.
Elliston JF; Katzenellenbogen BS
J Steroid Biochem; 1988 Jun; 29(6):559-69. PubMed ID: 3290576
[TBL] [Abstract][Full Text] [Related]
9. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
Pavlik EJ; Nelson K; Srinivasan S; Powell DE; Kenady DE; DePriest PD; Gallion HH; van Nagell JR
Cancer Res; 1992 Aug; 52(15):4106-12. PubMed ID: 1638522
[TBL] [Abstract][Full Text] [Related]
10. Ketononestrol aziridine, an agonistic estrogen receptor affinity label: study of its bioactivity and estrogen receptor covalent labeling.
Elliston JF; Zablocki JA; Katzenellenbogen BS; Katzenellenbogen JA
Endocrinology; 1987 Aug; 121(2):667-76. PubMed ID: 3595536
[TBL] [Abstract][Full Text] [Related]
11. Efficient and highly selective covalent labeling of the estrogen receptor with [3H]tamoxifen aziridine.
Katzenellenbogen JA; Carlson KE; Heiman DF; Robertson DW; Wei LL; Katzenellenbogen BS
J Biol Chem; 1983 Mar; 258(6):3487-95. PubMed ID: 6833211
[No Abstract] [Full Text] [Related]
12. Progesterone interaction with estrogen and antiestrogen in the rat uterus--receptor effects.
Koseki Y; Zava DT; Chamness GC; McGuire WL
Steroids; 1977 Aug; 30(2):169-77. PubMed ID: 201053
[TBL] [Abstract][Full Text] [Related]
13. Estrogenic stimulation of the antiestrogen specific binding site in rat uterus and liver.
Winneker RC; Clark JH
Endocrinology; 1983 Jun; 112(6):1910-5. PubMed ID: 6682755
[TBL] [Abstract][Full Text] [Related]
14. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
15. Cellular and molecular mechanism of action of antiestrogens.
Rochefort H; Borgna JL; Evans E
J Steroid Biochem; 1983 Jul; 19(1A):69-74. PubMed ID: 6887874
[TBL] [Abstract][Full Text] [Related]
16. Estrogen binding sites in the nucleus of normal and malignant human tissue: characteristics of the multiple nuclear binding sites.
Syne JS; Markaverich BM; Clark JH; Panko WB
Cancer Res; 1982 Nov; 42(11):4449-54. PubMed ID: 7127287
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma.
Kawamura I; Mizota T; Mukumoto S; Manda T; Masuda K; Nakamura T; Kubota H; Matsumoto S; Nishigaki F; Shimomura K
Arzneimittelforschung; 1989 Aug; 39(8):889-93. PubMed ID: 2818677
[TBL] [Abstract][Full Text] [Related]
18. [In vivo occupation of estrogen receptors by hydroxylated metabolites of tamoxifen].
Borgna JL; Rochefort H
C R Seances Acad Sci D; 1979 Dec; 289(15):1141-4. PubMed ID: 121266
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-receptor--DNA interaction. Difference between activation by estrogen and antiestrogen.
Evans E; Baskevitch PP; Rochefort H
Eur J Biochem; 1982 Nov; 128(1):185-91. PubMed ID: 7173202
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the role of antiestrogen-binding sites in mediating the growth modulatory effects of antiestrogens: studies using t-butylphenoxyethyl diethylamine, a compound lacking affinity for the estrogen receptor.
Sheen YY; Simpson DM; Katzenellenbogen BS
Endocrinology; 1985 Aug; 117(2):561-4. PubMed ID: 4017947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
